A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
Thirteen biochemical markers of infection and inflammation were measured during anti-Pseudomonas therapy in cystic fibrosis (CF) patients with respiratory exacerbation. The assessment of some of these markers is thought to be helpful in the evaluation of efficacy of antibiotic therapy in CF.
Valletta
E A
EA
Cystic Fibrosis Center, Verona, Italy.
Rigo
A
A
Bonazzi
L
L
Zanolla
L
L
Mastella
G
G
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011552:Pseudomonas Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D015415:Biomarkers